Non-Small Cell Lung Cancer

New Indication: Adjuvant Pembrolizumab for NSCLC

2023-03-15

  • Study

    Randomized, triple-blind, phase III trial
    Completely resected, pathologically confirmed stage IB (tumours of ≥4 cm in diameter), II, or IIIA
    Pembrolizumab (n=590) vs PBO (n=587)

  • Efficacy

    mDFS: 53.6 vs. 42 mos, HR: 0.76, p=0.0014

  • Safety

    Grade3 AEs: Hypertension (6% of both), pneumonia (2% vs.0)


    • Lancet Oncology,2022 OCT, 23 (10): p1274-1286

    Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

    http://doi.org/10.1016/S1470-2045(22)00518-6

    Reviewed by Elvin Chalabiyev, MD on Mar 15, 2023